Pharmaceutical Technology, Mar 1, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Mar 1, 2013
Articles
Advancing Polymers for Solubility Enhancement
By Adeline Siew, PhD
Pharmaceutical Technology brought together a panel of industry experts for a special forum to discuss solubilizing polymers and the related formulation strategies for poorly soluble drugs.
Continuous Improvement in Tablet Coating and Dry Granulation
By Martin Hack , Dejan Djuric
Recent advances in equipment design and operation in spraying, drying, and mixing can improve the tablet-coating process.
Standardizing Excipient Information to Achieve Supply-Chain Security
By Bretta Erskine Lichtenhan
The use of various documents and guides by the International Pharmaceutical Excipients Council can facilitate the flow of information among excipient manufacturers, distributors, and users.
Tackling Common Problems in Tableting and Tooling
By Adeline Siew, PhD
The tableting science anti-research (TSAR) project seeks to understand why certain formulations stick to tablet tooling.
Quality by Design in Excipients
By Patricia Van Arnum
Factors for assessing excipient variability, the associated challenges developers need to address to design and manufacture solid oral drug products, and solutions for such challenges are examined.
Concerns and Innovations in Tablet Splitting and Scoring
A roundtable discussion of the challenges and innovations in tablet splitting featuring Freeman Technology, Accu-Break Pharmaceuticals, and Medelpharm.
The Ph.Eur. approach to tablet splitting
An alternative chapter has been added to the European Pharmacopoeia for dosage uniformity.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here